• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Aprea - Articles and news items

Aprea announces efficacy and safety data for APR-246 in ovarian cancer

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

Aprea presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246 at the ASCO annual meeting…

Aprea closes EUR 46 million Series B financing round

Industry news / 9 March 2016 / Victoria White

Aprea says the funds will be used to advance the clinical development of its lead programme APR-246, a first-in-class anticancer compound reactivating the tumour suppressor protein p53…

Aprea announces preliminary study data for APR-246 in ovarian cancer

Industry news / 26 October 2015 / Victoria White

APR-246 combined with standard of care chemotherapy shows activity in the treatment of recurrent ovarian cancer…